loader
Please Wait
Applying Filters...
menu
    • menu

    Annual Sales of 5-(2-Fluorophenyl)-N-methyl-1-(3-pyridinylsulfonyl)-1H-pyrrole-3-methanamine (2E)-2-butenedioate reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

    Client Email Product
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    CHSD Vonoprazan Fumarate

    Virtual Booth

    Contact Supplier

    View Presentation

    Send me more info on How To Grow My Business Digitally?
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    SPI Pharma Corp Ad

    Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Menu

    5-(2-Fluorophenyl)-N-methyl-1-(3-pyridinylsulfonyl)-1H-pyrrole-3-methanamine (2E)-2-butenedioate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,857Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 1Takecab/Vocinti

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Takecab

    Vonoprazan Fumarate

    arrow
    Pharmaconex 2024
    Not Confirmed

    Brand Name : Takecab

    Japan
    arrow
    Pharmaconex 2024
    Not Confirmed

    Takeda

    Vonoprazan Fumarate

    Main Therapeutic Indication : Gastrointestinal Disorders

    Currency : USD

    2019 Revenue in Millions : 647

    2018 Revenue in Millions : 535

    Growth (%) : 21

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Takecab

    Vonoprazan Fumarate

    arrow
    Pharmaconex 2024
    Not Confirmed

    Brand Name : Takecab

    Japan
    arrow
    Pharmaconex 2024
    Not Confirmed

    Takeda

    Vonoprazan Fumarate

    Main Therapeutic Indication : Gastrointestinal Disorders

    Currency : USD

    2020 Revenue in Millions : 771

    2019 Revenue in Millions : 660

    Growth (%) : 17

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Takecab

    Vonoprazan Fumarate

    arrow
    Pharmaconex 2024
    Not Confirmed

    Brand Name : Takecab

    Japan
    arrow
    Pharmaconex 2024
    Not Confirmed

    Takeda

    Vonoprazan Fumarate

    Main Therapeutic Indication : Gastrointestinal Disorders

    Currency : USD

    2021 Revenue in Millions : 837

    2020 Revenue in Millions : 739

    Growth (%) : 22

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Takecab/Vocinti

    Vonoprazan Fumarate

    arrow
    Pharmaconex 2024
    Not Confirmed

    Brand Name : Takecab/Vocinti

    Japan
    arrow
    Pharmaconex 2024
    Not Confirmed

    Takeda

    Vonoprazan Fumarate

    Main Therapeutic Indication : Gastrointestinal Diseases

    Currency : USD

    2022 Revenue in Millions : 837

    2021 Revenue in Millions : 837

    Growth (%) : 0

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Takecab/Vocinti

    Vonoprazan Fumarate

    arrow
    Pharmaconex 2024
    Not Confirmed

    Brand Name : Takecab/Vocinti

    Japan
    arrow
    Pharmaconex 2024
    Not Confirmed

    Takeda

    Vonoprazan Fumarate

    Main Therapeutic Indication : Gastrointestinal Diseases

    Currency : USD

    2023 Revenue in Millions : 781

    2022 Revenue in Millions : 837

    Growth (%) : 6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Takecab

    Vonoprazan Fumarate

    arrow
    Pharmaconex 2024
    Not Confirmed

    Brand Name : Takecab

    Japan
    arrow
    Pharmaconex 2024
    Not Confirmed

    Takeda

    Vonoprazan Fumarate

    Main Therapeutic Indication : Gastrointestinal Disorders

    Currency : USD

    2016 Revenue in Millions : 276

    2015 Revenue in Millions : 50

    Growth (%) : 448

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Takecab

    Vonoprazan Fumarate

    arrow
    Pharmaconex 2024
    Not Confirmed

    Brand Name : Takecab

    Japan
    arrow
    Pharmaconex 2024
    Not Confirmed

    Takeda

    Vonoprazan Fumarate

    Main Therapeutic Indication : Gastrointestinal Disorders

    Currency : USD

    2017 Revenue in Millions : 494

    2016 Revenue in Millions : 295

    Growth (%) : 68

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Takecab

    Vonoprazan Fumarate

    arrow
    Pharmaconex 2024
    Not Confirmed

    Brand Name : Takecab

    Japan
    arrow
    Pharmaconex 2024
    Not Confirmed

    Takeda

    Vonoprazan Fumarate

    Main Therapeutic Indication : Gastrointestinal Disorders

    Currency : USD

    2018 Revenue in Millions : 518

    2017 Revenue in Millions : 464

    Growth (%) : 12%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF